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A B S T R A C T
Background: Low-grade inflammation is associated with depression, but studies of specific symptoms are rela-
tively scarce. Association between inflammatory markers and specific symptoms may provide insights into
potential mechanism of inflammation-related depression. Using longitudinal data, we have tested whether
childhood serum interleukin 6 (IL-6) and C-reactive protein (CRP) levels are associated with specific depressive
symptoms in early adulthood.
Methods: In the ALSPAC birth cohort, serum IL-6 and CRP levels were assessed at age 9 years and 19 depressive
symptoms were assessed at age 18 years. We used modified Poisson generalised linear regression with robust
error variance to estimate the risk ratio (RR) and 95% confidence interval (95% CI) for each depressive
symptom. In addition, we used confirmatory factor analysis to create two continuous latent variables re-
presenting somatic/neurovegetative and psychological dimension scores. Structural equation modelling was
used to test the associations between IL-6 and these dimension scores.
Results: Based on data from 2731 participants, IL-6 was associated with diurnal mood variation, concentration
difficulties, fatigue and sleep disturbances. The adjusted RRs for these symptoms at age 18 years for participants
in top, compared with bottom, third of IL-6 at age 9 years were 1.75 (95% CI, 1.13–2.69) for diurnal mood
variation, 1.50 (95% CI, 1.11–2.02) for concentration difficulties, 1.31 (95% CI, 1.12–1.54) for fatigue, and 1.24
(95% CI, 1.01–1.52) for sleep disturbances. At dimension level, IL-6 was associated with both somatic/neuro-
vegetative (β=0.059, SE= 0.024, P=0.013) and psychological (β=0.056, SE=0.023, P=0.016) scores.
Conclusions: Inflammation is associated with specific symptoms of depression. Associations with so-called so-
matic/neurovegetative symptoms of depression such as fatigue, sleep disturbances and diurnal mood variation
indicate that these symptoms could be useful treatment targets and markers of treatment response in clinical
trials of anti-inflammatory treatment for depression.
1. Introduction
An association between low-grade inflammation and depression is
well established. Meta-analyses of cross-sectional studies confirm that
serum concentrations of pro-inflammatory cytokines [e.g., interleukin 6
(IL-6)] and acute phase proteins [e.g., C-reactive protein (CRP)] are
elevated in acutely unwell patients with depression in comparison with
controls (Dowlati et al., 2010; Goldsmith et al., 2016; Haapakoski et al.,
2015; Howren et al., 2009). These elevated levels tend to normalise
after recovery upon treatment with antidepressants, but continue to
remain elevated in treatment resistant patients (Goldsmith et al., 2016;
Maes et al., 1997; O'Brien et al., 2007). Longitudinal studies reporting
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an association between higher levels of IL-6 and CRP in childhood/
adulthood and subsequent development (Gimeno et al., 2009;
Khandaker et al., 2014) and persistence (Khandaker et al., 2017b; Zalli
et al., 2016) of depressive symptoms indicate that inflammation could
be a cause, rather than simply a consequence of the illness.
Depression consists of a diverse range of symptoms. Inflammation
may contribute to pathogenesis of specific components of the syn-
drome. Symptoms such as fatigue, psychomotor retardation, impaired
sleep and change in appetite are often referred to as sickness behavior
or neurovegetative symptoms in the experimental animal literature
(Dantzer et al., 2008; Miller et al., 2009; Raison et al., 2006). The In-
ternational Classification of Diseases 10th Revision (ICD-10) diagnostic
criteria for depressive episode specifies these symptoms along with a
few others as somatic symptoms of depression (see below) (WHO,
1992). Somatic symptoms are different from psychological symptoms
(e.g., hopelessness and guilt) of depression phenomenologically (WHO,
1992) and perhaps physiologically (Jokela et al., 2016). Cross-sectional
studies indicate that low-grade inflammation, as measured by elevated
serum CRP levels, is associated with somatic symptoms (e.g., fatigue,
impaired sleep and activity levels) but not with psychological symp-
toms within the general population or in depressed patients (Jokela
et al., 2016; Kohler-Forsberg et al., 2017). However, these studies did
not compare effect estimates for somatic and psychological dimensions
directly. Atypical features of depression, particularly increased appetite
or weight, are associated with a number of genetic risk variants for
body mass index (BMI) and levels of CRP and leptin (Milaneschi et al.,
2017). These findings support the idea that different depressive symp-
toms may have distinct pathophysiological mechanisms. Association
between markers of inflammation and specific symptoms may provide
important clues regarding potential mechanisms of inflammation-re-
lated depression. However, longitudinal studies of inflammatory mar-
kers and specific symptoms of depression are scarce.
Using data from the general population-representative Avon
Longitudinal Study of Parents and Children (ALSPAC) birth cohort, we
previously reported a longitudinal association between serum IL-6 le-
vels in childhood at age 9 years and risk of depression and psychosis
subsequently in early adulthood at age 18 years (Khandaker et al.,
2014). In order to gain further insight into the relationship between
inflammation and depression, we present another longitudinal study
based on the ALSPAC cohort that examines the relationships between
IL-6 and CRP at age 9 years and 19 specific symptoms of depression
assessed at age 18 years. In addition to using individual depressive
symptoms, we created two latent variables representing somatic/neu-
rovegetative and psychological symptom dimension scores. We hy-
pothesised that childhood inflammatory markers would be associated
with specific depressive symptoms in early adulthood.
2. Methods
2.1. Description of cohort and sample selection
ALSPAC is a general population-based birth cohort in the former
Avon County in the South West region of England. 14,541 pregnant
women who were residents of the study catchment areas and had ex-
pected delivery dates between April 1st, 1991 and December 31st, 1992
were initially recruited into the cohort, resulting in 14,062 live births.
Additional children and parents were subsequently recruited into the
cohort. Since age 7 years, the children attended annual clinical assess-
ments during which they participated in various face-to-face interviews
and physical tests. Detailed information about the ALSPAC cohort can
be found on the study website (http://www.bristol.ac.uk/alspac), and
the sample characteristics and methodology have been previously de-
scribed (Boyd et al., 2013; Fraser et al., 2013). For information on all
available ALSPAC data, a fully searchable data dictionary is also
available (http://www.bris.ac.uk/alspac/researchers/data-access/data-
dictionary).
The risk sets for the analyses presented here were comprised of 5074
and 5086 participants who provided enough blood during clinical as-
sessments at age 9 years to measure serum IL-6 and CRP levels, re-
spectively (Supplementary Fig. 1). 2731 participants with baseline IL-6
data had also attended the follow-up assessment for depressive symp-
toms at age 18 years; this analytic sample was used to assess associa-
tions between IL-6 and depressive symptoms. The analytic sample for
CRP was similar (n= 2738). Ethical approval for the study was ob-
tained from the ALSPAC Ethics and Law Committee and the Local Re-
search Ethics Committees.
2.2. Measurement of inflammatory markers
Blood samples collected from non-fasting 9-year-old participants
(mean age: 119.0months; SD: 3.9 months) during clinical assessments
were immediately centrifuged; serum samples were frozen at −80 °C in
1mL aliquots. After a median storage period of 7.5 years, IL-6 and CRP
levels were assayed in 2008. There was no evidence of freeze-thaw
cycles during storage.
Serum high sensitivity CRP levels were measured using an auto-
mated particle-enhanced immunoturbidimetric assay (Roche, Welwyn
Garden City, UK). The minimum detection limit was 0.03mg/L. CRP
values in the entire sample (n= 5086) ranged from 0.01 to 67.44mg/L;
mean (SD) = 0.80 (2.72) mg/L. Serum IL-6 levels were measured using
an enzyme-linked immunosorbent assay (ELISA) (R&D Systems, UK).
The minimum detection limit was 0.007 pg/mL. IL-6 values in the en-
tire sample (n= 5074) ranged from 0.007 to 20.051 pg/mL; mean
(SD)=1.28 (1.59) pg/mL. All inter-assay and intra-assay coefficients of
variation for IL-6 and CRP were<5%. No other inflammatory markers
were measured from blood samples collected at age 9 years.
Serum IL-6 and CRP levels were analysed as categorical variables.
The distributions of serum CRP values (n=5086) and serum IL-6 va-
lues (n=5074) were divided into three categories (bottom, middle and
top thirds) based on their respective distribution tertiles (66th and 33rd
percentiles for CRP were 0.37 and 0.14mg/L, respectively; 66th and
33rd percentiles for IL-6 were 1.12 and 0.59 pg/mL, respectively).
Statistical cut-offs were chosen due to the lack of accepted cut-off va-
lues for IL-6 and CRP in defining low-grade inflammation in children.
We carried out additional analysis using IL-6 quartiles. Serum IL-6 and
CRP levels were also analysed as standardised continuous variables (z-
transformed values).
2.3. Psychiatric measures
2.3.1. Assessment of depressive symptoms at age 18 years
In assessment clinics held over the course of a few months, de-
pressive symptoms were assessed in 18-year-old participants (mean age:
213.6months; SD: 5.1months) using a self-administered computerized
version of the Clinical Interview Schedule-Revised (CIS-R). CIS-R is a
standardised and validated tool commonly used to assess depression
and anxiety in community-based samples (Lewis et al., 1992). As pri-
mary outcomes, we used all available specific depressive symptom level
data gathered by CIS-R as individual variables. A total of 19 depressive
symptoms were measured: fatigue, sleep disturbances, concentration
difficulties, irritability, depressed/low mood, suicidality, worry,
phobia, anxiety, panic, psychomotor change, change in appetite/
weight, diurnal variation in mood, anhedonia, hopelessness, low self-
esteem, self-blame, decreased libido and physical symptoms. Because
we were interested in clinically significant depressive symptoms, we re-
coded all depressive symptom as binary variables based on a clinically
meaningful cut-off. Please see Supplementary Methods for full in-
formation on the data re-coding. Supplementary Table 1 presents a
complete breakdown of responses to each symptom category, as ori-
ginally coded by CIS-R, and for the re-coded variables.
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2.3.2. Somatic/neurovegetative and psychological symptoms of depression
Somatic syndrome is recognised as a part of the diagnosis of de-
pressive episode (F32) according to the ICD-10 diagnostic criteria for
research (ICD-10: DCR-10) (WHO, 1992). We selected the following
seven symptoms as somatic/neurovegetative based on this criteria:
anhedonia, diurnal variation in mood, psychomotor change, change in
appetite/weight, fatigue, sleep disturbances and decreased libido. The
following seven symptoms were classified as psychological: depressed/
low mood, concentration difficulties, irritability, hopelessness, self-
blame, low self-esteem and suicidality. Each symptom was considered
as a separate outcome variable. In addition, we carried out con-
firmatory factor analysis (CFA) to create two factor scores representing
somatic/neurovegetative and psychological dimensions using the seven
respective individual symptoms listed above.
2.4. Assessment of covariates
We included age, sex, father’s occupation, ethnicity, BMI and self-
reported infections around blood collection as potential confounders.
Because not every participant was exactly 18 years old at the time of
outcome assessment, age was recorded at the time of outcome assess-
ment in months and was used as a continuous variable. Sex was re-
corded at birth and treated as a binary variable. Father's occupation was
recorded at birth according to the UK Office of National Statistics' so-
cioeconomic classification system (Class I= professionals and higher
managerial workers; II = intermediate occupations; IIIa= skilled non-
manual occupations; IIIb= skilled manual occupations; IV= partly
skilled occupations; V= unskilled occupations) (Statistics, 1980). This
was re-coded as a binary variable with non-manual (I, II, and IIIa) and
manual occupations (IIIb, IV, and V). Ethnicity was recorded at birth
and originally coded as a categorical variable (White, Black Caribbean,
Black African, Other Black, India, Pakistani, Bangladeshi, Chinese and
Other). Ethnicity was re-coded as a binary variable (British White and
Non-white) because the study sample was predominantly made up of
British White participants (97.4%). BMI was assessed at the time of
blood collection and recorded as a continuous variable. Self-reported
infection status at the time or week before blood collection was re-
corded during the clinical assessment at age 9 years and used as a
binary variable (i.e. infection present or absent).
2.5. Statistical analysis
2.5.1. Comparison of baseline characteristics
Sociodemographic and other characteristics were compared among
groups with low, medium and high IL-6 at age 9 years. One-way ana-
lysis of variance (ANOVA) was used for normally distributed con-
tinuous variables; Kruskal-Wallis test was used for non-normally dis-
tributed continuous variables; and Chi-squared test was used for
categorical variables.
2.5.2. Association between inflammatory markers and specific symptoms of
depression
We used modified Poisson generalised linear regression with robust
error variance to estimate the risk ratio (RR) and 95% confidence interval
(CI) for each depressive symptom at age 18 years for participants in the top
and middle, compared with the bottom, thirds of the serum IL-6 distribution
at age 9 years. The same approach was taken for CRP. All regression models
were adjusted for age, sex, father's occupation, ethnicity, BMI and self-re-
ported infection. Adjusted RRs (95% CIs) were plotted on forest plots. P-
values for unadjusted RRs for IL-6 were corrected for multiple testing using
the Holm–Bonferroni method (Holm, 1979). This method is similar to the
Bonferroni, yet less stringent. Some have argued that this method is better
than Bonferroni for public health research (Aickin and Gensler, 1996). For a
step-by-step guide on how this correction is calculated, along with an ex-
ample, please see: http://nebc.nerc.ac.uk/courses/GeneSpring/GS_
Mar2006/Multiple%20testing%20corrections.pdf.
2.5.3. Association between inflammatory markers and symptom dimension
scores
First, we carried out CFA to test whether a unidimensional or two-
factor model provided better fit for the symptom data (7 somatic/
neurovegetative and 7 psychological symptoms) using the full in-
formation maximum likelihood (FIML) estimator. FIML allows for di-
rect comparison of both models. The results showed that two-factor
model was marginally better than one-factor model (unidimensional:
AIC= 42376, BIC=42556; two-factor: AIC= 42351, BIC= 42538).
We then added IL-6 into the model to test the association between IL-6
and two continuous latent variables/factors that represented somatic/
neurovegetative and psychological dimensions. This was a structural
equation model (SEM), which computed path coefficients, standard
errors (SEs) and P-values for the association of IL-6 (standardised
continuous variable) with these latent variables. The estimated coeffi-
cients are on the probit scale and represent changes in the symptom
dimension standardised scores (Z-scores) per SD change in IL-6 levels.
In addition, we used a T-test to examine whether coefficients for so-
matic/neurovegetative and psychological dimensions were significantly
different from each other.
3. Results
3.1. Baseline characteristics of sample
Participants in the top third of IL-6 levels at baseline were more
likely to be female, have higher BMI and have a self-reported infection
around the time of blood collection at age 9 years. However, the dis-
tributions of age, British white ethnicity and father's non-manual oc-
cupations were similar across the thirds of IL-6 (Table 1).
3.2. Prevalence of specific symptoms of depression at age 18 years
Data on 19 specific symptoms of depression were available for a
total of 4568 participants. Fatigue (31.5%), hopelessness (31.1%) and
change in appetite/weight (28.1%) were the most prevalent symptoms,
while phobia (6.7%), decreased libido (4.5%) and panic (2.1%) were
the least prevalent symptoms (Supplementary Table 1).
3.3. Association between inflammatory markers and specific symptoms of
depression
IL-6 at age 9 years was associated with diurnal variation in mood,
concentration difficulties, fatigue and sleep disturbances at age 18 years
after adjusting for potential confounders (Fig. 1; Supplementary
Table 2). The adjusted RRs (95% CI) for diurnal variation in mood,
concentration difficulties, fatigue and sleep disturbances were 1.75
(1.13–2.69), 1.50 (1.11–2.02), 1.31 (1.12–1.54), and 1.24 (1.01–1.52),
respectively, for participants in the top, compared with the bottom,
third of IL-6 at age 9. CRP was associated with fatigue, change in ap-
petite/weight, and irritability in the unadjusted analysis; however,
these associations became attenuated after controlling for potential
confounders (Fig. 2; Supplementary Table 3).
Sensitivity analyses using quartiles of IL-6 showed that IL-6 was
associated with fatigue, diurnal variation in mood, concentration dif-
ficulties and hopelessness after controlling for potential confounders for
participants in the top quartile of IL-6 distribution compared with those
in the bottom quartile. There was also trend level association of IL-6
with anhedonia, psychomotor change and low self-esteem. Please see
Supplementary Table 4.
3.4. Association between inflammatory markers and symptom dimension
scores
SEM analysis testing the association between IL-6 and two latent
variables representing depressive symptom dimensions showed that IL-
A.L. Chu et al. Brain, Behavior, and Immunity xxx (xxxx) xxx–xxx
3
6 was associated with both somatic/neurovegetative (co-effi-
cient= 0.059, SE= 0.024, P=0.013) and psychological dimensions
(co-efficient= 0.056, SE=0.023, P=0.016); see Fig. 3. In other
words, a SD change in IL-6 levels translated to a change in the Z-scores
by 0.059 points for the somatic/neurovegetative dimension and 0.056
points for the psychological dimension. A t-test comparing the coeffi-
cients did not show a statistically significant difference (P=0.379).
3.5. Effect of multiple testing
IL-6 was associated with 11 depressive symptoms before adjusting
for potential confounders (Supplementary Table 2). Evidence for asso-
ciation remained for three symptoms (fatigue, sleep disturbances and
hopelessness) after correcting observed P-values for multiple testing
(Table 2).
Table 1
Baseline Characteristics of Participants by the Distribution of Serum IL-6 Values at Age 9 Years.
Characteristic Distribution of Serum IL-6 Levels at Age 9 Yearsa P-valueb
Bottom Third Middle Third Top Third
Total no. of participants 1674 1675 1725
Age (months) at outcome, mean (SD)c 212.9 (4.6) 213.2 (4.7) 213.3 (4.9) 0.11
Male sex, no. (%) 988 (59.0) 852 (50.9) 721 (41.8) <0.001
BMI at age 9 years, median (IQR)d 16.4 (15.4–17.8) 17.0 (15.6–18.9) 17.7 (16.0–20.3) <0.001
British white ethnicity, no. (%)e 1532 (98.4) 1506 (98.2) 1527 (97.8) 0.47
Father’s occupation, non-manual, no. (%)f 926 (63.6) 871 (61.3) 854 (60.0) 0.13
Self-reported infection at age 9 years, no. (%)g 83 (5.0) 149 (8.9) 248 (14.4) <0.001
Abbreviations: BMI=Body Mass Index; IL-6= Interleukin 6; IQR= Interquartile Range (range of values between the 25th and 75th percentile data values);
No.=Number; SD=Standard Deviation
a Participants in the IL-6 risk set at age 9 years were divided into thirds based on the tertiles of the serum IL-6 distribution; the cut-offs for the top (66th percentile)
and bottom (33rd percentile) tertiles were 1.12 and 0.59 pg/mL, respectively
b ANOVA was used to assess mean ages across the thirds of IL-6 at age 9 years; the Kruskal-Wallis test was used to assess median BMI at age 9 years across the thirds
of IL-6 at age 9 years; the Chi-squared test for proportions was used to test equal proportions of categorical characteristics (sex, ethnicity, father’s occupation and
infection status at age 9 years) between the thirds of IL-6 at age 9 years
c Data on age at age 18 years was available for only 2995 participants in the three categories; the sample sizes for the bottom, middle and top thirds were 990, 983
and 1022, respectively
d The median value and IQR for BMI at age 9 years was reported due to a lack of normality in the distribution of BMI values; data on BMI was available for only
5018 participants in the three categories; the sample sizes for the bottom, middle and top thirds were 1653, 1660, and 1705, respectively
e Data on ethnicity was available for only 4651 participants in the three categories; the denominators for the bottom, middle and top thirds were 1557, 1533, and
1561, respectively
f Data on father’s occupation was available for only 4300 participants in the three categories; the denominators for the bottom, middle and top thirds were 1455,
1422, and 1423, respectively
g Data on infection status at age 9 years was available for only 5065 participants in the three categories; the denominators for the bottom, middle and top thirds
were 1672, 1672, and 1721, respectively
Fig. 1. Adjusted risk ratios (RR) and 95%
CIs for symptoms of depression at age
18 years for participants in the top, com-
pared with bottom, third of serum IL-6 le-
vels at age 9 years
Footnote: The forest plot displays the ad-
justed RRs (95% CIs) for all 19 depressive
symptoms at age 18 years when comparing
participants in the top third with those in
the bottom third of serum IL-6 levels at age
9 years. The RRs were adjusted for age at the
time of outcome assessment, sex, ethnicity,
father’s occupation, BMI at age 9 years and
self-reported infection at age 9 years.
Fatigue, sleep disturbances, concentration
difficulties and diurnal variation in mood
remained associated with IL-6 after ad-
justing for confounding.
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3.6. Effect of missing data
To explore the potential impact of differential participant attrition
over time, we compared participants in the IL-6 analytic sample (i.e.
data present for both IL-6 and depressive symptom) with those in the
missing sample (i.e. data present for IL-6 and missing depressive
symptom). IL-6 levels, BMI, self-reported infection and British White
ethnicity were similar between the analytic and missing samples
(Online Supplementary Table 4). However, participants in the missing
sample were more likely to be older, male and have a poorer socio-
economic status (fathers with manual occupations) compared to those
in the analytic sample.
3.7. Effect of acute infection
We re-tested the associations between CRP and depressive symp-
toms after excluding 60 participants (1.2% of a total of 5086 partici-
pants) who had serum CRP levels> 10mg/L, an indicator of possible
Fig. 2. Adjusted risk ratios (RR) and 95%
CIs for symptoms of depression at age
18 years for participants in the top, com-
pared with bottom, third of serum CRP le-
vels at age 9 years
Footnote: The forest plot displays the ad-
justed RRs (95% CIs) for all 19 depressive
symptoms at age 18 years when comparing
participants in the top third with those in
the bottom third of serum CRP levels at age
9 years. The RRs were adjusted for age at the
time of outcome assessment, sex, ethnicity,
father’s occupation, BMI at age 9 years and
self-reported infection at age 9 years. CRP
was not associated with depressive symp-
toms after adjusting for confounding.
Fig. 3. Structural Equation Model Testing the Association of IL-6 with Somatic/Neurovegetative and Psychological Symptom Latent Variables
Footnote: Confirmatory factor analysis computed somatic and psychological factors, which were used as outcome variables in relation to IL-6 in SEM. The path co-
efficient for the association between IL and 6 and the somatic factor was adjusted for the psychological factor, and vice versa.
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acute infection. The results remained virtually unchanged. CRP was not
associated with any depressive symptom after adjusting for potential
confounders (Online Supplementary Table 5).
4. Discussion
Using longitudinal data from a general population-representative
birth cohort, we have examined associations between childhood IL-6
and CRP levels and specific symptoms of depression in early adulthood.
Individual symptom level analysis indicated that IL-6 was associated
with diurnal mood variation, concentration difficulties, fatigue and
sleep disturbances after adjusting for potential confounders. Further
analyses using latent variables showed that IL-6 was associated with
both somatic/neurovegetative and psychological dimension scores.
Adjusting for confounding had a more pronounced effect on the asso-
ciation between CRP and depressive symptoms; CRP was not associated
with any depressive symptom after adjusting for confounders.
To our knowledge, this is one of the first general population-based
longitudinal studies to investigate the association between in-
flammatory markers and specific depressive symptoms. Low-grade in-
flammation, as defined by elevated serum concentrations of IL-6 and
CRP, is associated with the diagnosis of depression (Dowlati et al.,
2010; Goldsmith et al., 2016; Haapakoski et al., 2015; Howren et al.,
2009), depressive symptom severity (Jokela et al., 2016; Kohler-
Forsberg et al., 2017; Moieni et al., 2015) and persistent depressive
symptoms (Khandaker et al., 2017b; Zalli et al., 2016). Cross-sectional
studies have reported an association between inflammatory markers
and somatic symptoms of depression such as fatigue, sleep disturbances
and change in appetite and activity levels (Case and Stewart, 2014;
Jokela et al., 2016; Kohler-Forsberg et al., 2017). We have replicated
some of these findings using a longitudinal design where inflammatory
markers were measured years before depressive symptoms developed.
These findings are consistent with existing literature, which suggests
that inflammation may be a cause for depressive symptoms, rather than
simply be a consequence of the illness (Gimeno et al., 2009; Khandaker
et al., 2014, 2017a).
In our analysis, inflammatory cytokine IL-6 was associated with so-
called somatic/neurovegetative symptoms such as fatigue, sleep dis-
turbances and diurnal variation in mood. This is consistent with find-
ings from the NESDA cohort, which reported that inflammatory
markers were specifically associated with somatic symptoms of de-
pression such as fatigue, weight gain and sleep disturbances (Duivis
et al., 2013). Similarly, immuno-activation in animals and healthy vo-
lunteers leads to fatigue, psychomotor retardation and anhedonia,
which are typical somatic symptoms according to ICD-10 diagnostic
criteria for depressive episode (Brydon et al., 2008; Capuron et al.,
2012; Eisenberger et al., 2010; Harrison et al., 2009, 2015). Features of
sickness behavior (e.g., fatigue) develop rapidly in the majority of in-
terferon-treated cancer patients who develop depression, while psy-
chological symptoms (e.g., low mood) develop slowly and relatively
less frequently (Capuron et al., 2009, 2002). Inflammation-induced
somatic/neurovegetative symptoms could be important mediators of
the relationship between inflammation and depression. Experimental
studies including clinical trials in humans are required to test this hy-
pothesis.
One possibility is that somatic/neurovegetative symptoms affect
mood by altering reward perception. Although the association between
IL-6 and anhedonia was no longer statistically significant after adjusting
for confounding within our dataset, previous experimental studies have
reported an association between inflammation and anhedonia. In non-
human primates chronic low-dose infusion of interferon-alpha leads to
reduction in striatal dopamine release and anhedonia-like behavior
(Felger et al., 2013). In patients with depression, plasma CRP con-
centration is associated with left basal ganglia glutamate levels, which,
in turn, is associated with psychomotor slowing and anhedonia (Felger
et al., 2016; Haroon et al., 2016). In healthy volunteers, experimental
immuno-activation alters activation of reward-related brain regions
(Brydon et al., 2008; Capuron et al., 2012; Eisenberger et al., 2010;
Harrison et al., 2009, 2015), including reduction in the ventral striatum
responses to hedonic reward (Capuron et al., 2012; Eisenberger et al.,
2010). In the future, RCTs and animal experimental studies could test
whether altered reward perception mediate the relationship between
somatic/neurovegetative symptoms and cognitive/psychological
symptoms of depression following immuno-modulation.
Association of inflammation with specific symptoms indicate that
these symptoms could be important treatment targets and markers of
treatment response in clinical trials of anti-inflammatory drugs for de-
pression. Selecting patients based on inflammation levels may be a
fruitful strategy for clinical trials of anti-inflammatory drugs
(Kappelmann et al., 2018; Raison et al., 2013). Similarly, focusing on
specific symptoms or symptom dimensions as outcomes may also be
useful. Somatic/neurovegetative symptoms such as fatigue and sleep
disturbances have considerable negative impact on daily functioning
and quality of life in patients with physical illness (Janardhan and
Bakshi, 2002). There is little work on the impact of somatic/neurove-
getative symptoms on quality of life in patients with depression. Studies
exploring the burden and impact of these symptoms in patients with
depression are required.
We have defined certain depressive symptoms as ‘somatic/neuro-
vegetative’ based on the ICD-10: DCR-10 criteria for depressive episode,
somatic syndrome (see Methods) (WHO, 1992). This is also informed by
the experimental animal literature, where certain inflammation-in-
duced symptoms such as anorexia, decreased motor activity, loss of
interest and sleep disturbances are often described as sickness behavior
or neurovegetative symptoms (Dantzer et al., 2008). The ICD-10 so-
matic symptoms of depression can be broadly seen as the human ana-
logue of animal neurovegetative symptoms because these symptoms
overlap, albeit not completely. However, we acknowledge that there
are inconsistencies in the use of the term ‘somatic’ in the literature. It
has also been used to refer to bodily distress, such as palpitations,
tightness of the chest, pain, etc. (Kapfhammer, 2006). This is not the
same as the somatic syndrome currently defined by ICD-10: DCR:10
criteria for depression. Our use of the term is conceptually aligned with
the ICD-10 definition of somatic syndrome in humans and inflamma-
tion-induced neurovegetative symptoms in animal studies, rather than
bodily distress reflecting worry.
Table 2
Corrected P-values for the Association between IL-6 and Depressive Symptoms
using the Holm–Bonferroni Method.
Depressive Symptom Original P-valuea Corrected P-value
Fatigue 3.6× 10^−7 0.0000038
Sleep disturbances 0.001 0.018
Concentration difficulties 0.008 0.120
Irritability 0.016 0.208
Depressed/low mood 0.215 0.860
Suicidality 0.093 0.588
Worry 0.040 0.400
Phobia 0.020 0.240
Anxiety 0.118 0.590
Panic 0.988 0.988
Psychomotor change 0.027 0.297
Change in appetite/weight 0.293 0.879
Diurnal mood variation 0.052 0.468
Anhedonia 0.013 0.182
Hopelessness 0.001 0.018
Low self-esteem 0.004 0.064
Self-blame 0.084 0.588
Decreased libido 0.301 0.879
Physical symptoms 0.062 0.496
a The P-values correspond to unadjusted RRs presented in Supplementary
Table 2: RR for each symptom at age 18 years for participants in the top,
compared with bottom, third of the distribution of serum IL-6 levels at age 9.
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Strengths of this study include a relatively large general population-
based sample, longitudinal design and assessment of an array of de-
pressive symptoms, 19 in total. However, there are some key limita-
tions. Firstly, CRP was not associated with any depressive symptom
which was surprising since IL-6 is a key inducer of CRP (Janeway et al.,
2001). The use of non-fasting blood samples may have increased
measurement error and is likely to have biased the findings toward the
null. We adjusted our results for a number of potential confounders, but
residual confounding could still be an alternative explanation for the
observed associations between IL-6 and somatic symptoms. However,
our work using Mendelian randomization analysis suggest that the as-
sociation between IL-6/CRP and depression is likely to be causal
(Khandaker et al., 2018a,b).
Serum IL-6 and CRP levels in our sample were generally low
(Section 2.2), which could be due to the young age of the participants.
The reported mean serum CRP levels in adults (mean age: 57 years)
within a large community-based Danish study were higher in compar-
ison with those in the relatively young ALSPAC sample aged 9 years. In
the Danish sample, CRP levels further increased after a 10-year follow-
up period (Wium-Andersen et al., 2013).
Another significant limitation is the attrition of study participants
between the time points of blood collection and depressive symptom
assessment. Missingness was associated with older age, male sex and
poorer SES. Older age and lower SES are both associated with depres-
sion. An over-representation of individuals within these groups within
the missing sample could introduce a bias towards the null. Therefore,
we are likely to have underestimated the true association between IL
and 6 and specific depressive symptoms.
In summary, our findings indicate that childhood IL-6 levels are asso-
ciated with specific symptoms of depression in early adulthood. Associations
with so-called somatic/neurovegetative symptoms such as fatigue, sleep
disturbances and diurnal mood variation indicate that these symptoms
could be useful treatment targets and markers of treatment response in
clinical trials of anti-inflammatory drugs for depression.
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